logo-loader
viewProactive Group

Investor Update: Faron Pharma's YODA study confirms Traumakine suspicions

Top stories from the Proactive Investors UK newsroom.

The much awaited feasibility study on Asiamet’s (LON:ARS) BKM project’s out this morning revealing an initial 9 year mine life producing up to 25,000 tonnes of copper cathode a year. The Post Tax NPV’s come in at $133.5 million.

Immotion Group PLC (LON:IMMO) has signed a three-year deal with Survios, a virtual reality (VR) studio backed by media firm MGM, for content to install in its new VR Arena.

Faron Pharmaceuticals Oy (LON:FARN) has released the final results of the YODA study into its interferon-beta drug Traumakine.  A phase III clinical trial – called “INTEREST” - on patients with a condition called acute respiratory distress syndrome didn’t yield the anticipated results, and the YODA study was instigated to find out why.

Frontier IP Group PLC’s (LON:FIPP) portfolio firm Exscientia has entered a drug discovery collaboration with Shanghai-based biotech GT Apeiron Therapeutics. As part of the partnership Exscientia was entitled to become a GT Apeiron shareholder and receive milestone payments and royalties based on the clinical and commercial success of its drug discovery programme

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

PCF Bank's Scott Maybury reports on strong lending growth and increased...

PCF Group Plc's (LON:PCF) Scott Maybury speaks to Proactive London's Andrew Scott after the specialist lender posted record numbers in its latest year. Loans outstanding rose 55% to £339mln with profits for the twelve months to September climbing by 54% to £8mln. Maybury says targets for a...

9 hours, 13 minutes ago

2 min read